PMID- 23917391
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20211021
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 33
IP  - 2
DP  - 2014 Feb
TI  - Association of biomarkers of inflammation, cartilage and bone turnover with 
      gender, disease activity, radiological damage and sacroiliitis by magnetic 
      resonance imaging in patients with early spondyloarthritis.
PG  - 237-41
LID - 10.1007/s10067-013-2349-5 [doi]
AB  - To assess the association between biomarkers of inflammation, cartilage and bone 
      turnover with gender, Bath Ankylosing Spondylitis Disease Activity Index 
      (BASDAI), Spondylitis Disease Activity Score (ASDAS) and bone marrow oedema in 
      resonance magnetic imaging (MRI) of sacroiliac joints (SIJs) and radiological 
      damage in early spondyloarthritis (SpA). Cross-sectional study of 60 patients 
      (56.7 % females; mean age, 32.4 years) with early SpA. Sociodemographic data, 
      clinical features, serum matrix metalloproteinase 3 (MMP-3), high sensitivity 
      C-reactive protein (hsCRP), C-terminal cross-linking telopeptides of type I 
      collagen (CTX-I) and urinary deoxypyridinoline, ASDAS, BASDAI, BASFI, BASRI and 
      MRI of the SIJs were collected. The mean (SD) disease duration was 12.4 (6.8 
      months). Twenty-two (68.7 %) of the 32 patients had active sacroiliitis by MRI. 
      MMP-3 and CTX I correlated with swollen joint (r = 0.515, r = 0.386, p = 0.01). 
      hsCRP correlated with ESR (r = 0.303, p = 0.05), with CRP (r = 0.455, p = 0.01) 
      and with total BASRI (r = 0.95, p = 0.05). Biomarkers were unrelated with the 
      rest of variables. Levels of MMP-3 (44.3 +/- 52.4 vs 24.7 +/- 33.4, p < 0.05) and 
      CTX-I (0.53 +/- 0.45 vs 0.24 +/- 0.38; p < 0.05) were higher in men. Our study shows 
      that CTX-I and MMP-3 are a marker of peripheral disease activity in early SpA. 
      Male gender had higher levels of CTX-I and MMP-3, which may indicate higher 
      disease activity. Higher hsCRP levels trended towards correlation with more 
      baseline radiographic damage. Therefore, these biomarkers may help identify a 
      subgroup of patients who will need closer monitoring and more intensive 
      treatment.
FAU - Almodovar, Raquel
AU  - Almodovar R
AD  - Rheumatology Unit, Hospital Universitario Fundacion Alcorcon, Avda. Budapest s/n, 
      28922, Alcorcon, Madrid, Spain, ralmodovar@fhalcorcon.es.
FAU - Rios, Valeria
AU  - Rios V
FAU - Ocana, Sara
AU  - Ocana S
FAU - Gobbo, Milena
AU  - Gobbo M
FAU - Casas, Maria-Luisa
AU  - Casas ML
FAU - Zarco-Montejo, Pedro
AU  - Zarco-Montejo P
FAU - Juanola, Xavier
AU  - Juanola X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130807
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Amino Acids)
RN  - 0 (Biomarkers)
RN  - 0 (Collagen Type I)
RN  - 0 (Peptides)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - 90032-33-0 (deoxypyridinoline)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Amino Acids/urine
MH  - Biomarkers/blood
MH  - *Bone Remodeling
MH  - Bone and Bones/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Cartilage/*metabolism
MH  - Collagen Type I/blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Inflammation/*blood
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Peptides/blood
MH  - Sacroiliitis/*blood/pathology
MH  - Sex Factors
MH  - Spondylitis, Ankylosing/*blood/*pathology
MH  - Treatment Outcome
EDAT- 2013/08/07 06:00
MHDA- 2014/09/30 06:00
CRDT- 2013/08/07 06:00
PHST- 2013/06/07 00:00 [received]
PHST- 2013/07/21 00:00 [accepted]
PHST- 2013/07/08 00:00 [revised]
PHST- 2013/08/07 06:00 [entrez]
PHST- 2013/08/07 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - 10.1007/s10067-013-2349-5 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2014 Feb;33(2):237-41. doi: 10.1007/s10067-013-2349-5. Epub 2013 
      Aug 7.